Sunpharma Q3 Result: Net Profit Hits Rs. 3,033 Crore, Key Highlights

Table of Contents

Sunpharma Q3 Result: Key Highlights and Analysis

Sunpharma Q3 Result: Key Highlights and Analysis

Performance Overview

Sunpharma Q3 Result: Sun Pharmaceutical Industries Ltd. (Sunpharma) has released its Q3 financial results, showing notable growth across various metrics. The company’s net profit stood at Rs. 3,033 crore, compared to Rs. 2,912 crore in the same period last year. Revenue also saw an increase, reaching Rs. 13,675 crore from Rs. 12,380 crore.

Key Financial Metrics

Net Profit: Rs. 3,033 crore (previous year: Rs. 2,912 crore)
Revenue: Rs. 13,675 crore (previous year: Rs. 12,380 crore)
EBITDA: Rs. 4,007 crore (previous year: Rs. 3,480 crore)
Margins: 29.3% (previous year: 28%)

Sunpharma Q3 Performance Compared to Estimates

Sunpharma’s Q3 results surpassed market expectations in some areas, while falling short in others:

Net Profit: Rs. 2,913 crore (estimate: Rs. 2,879 crore)
Revenue: Rs. 13,675 crore (estimate: Rs. 13,208 crore)
EBITDA: Rs. 3,312 crore (estimate: Rs. 3,700 crore)
Margins: 24.2% (estimate: 28%)

Sales Breakdown

India Formulation Sales

Sunpharma’s India formulation sales reached Rs. 43,004 crore, marking a 13.8% growth from the previous year.

US Formulation Sales

Sales in the US were slightly lower at $474 million, showing a decline of 0.7% compared to last year.

Global Specialty Sales

Global specialty sales stood at $370 million, including a $45 million milestone. Excluding this milestone, specialty sales increased by 17.5%, accounting for 21% of the total sales for Q3.

Emerging Markets and Rest of World Sales

Emerging Markets: Sales reached $277 million, a growth of 10.1%.
Rest of World: Sales were up 21%, reaching $259 million.

Investment in Research and Development

Sunpharma invested Rs. 8,450 million in R&D during Q3, compared to Rs. 8,245 million in the same period last year. This continued investment underscores the company’s focus on innovation.

EBITDA and Margins

The EBITDA for Q3 was Rs. 40,090 million, including other operating revenues, representing a 15.3% increase. The EBITDA margin stood at 29.3%.

Adjusted and Reported Net Profit

Adjusted Net Profit: Rs. 32,196 million (up 24.1% excluding exceptional items)
Reported Net Profit: Rs. 29,034 million (previous year: Rs. 25,238 million)

Notable Achievements

Gross sales grew by 10.5%, reaching Rs. 134,369 million.
Specialty products made up 21% of total sales for Q3, indicating a strategic shift toward high-value offerings.

FAQs

1. How did Sunpharma perform in Q3 compared to last year?
Sunpharma’s net profit grew to Rs. 3,033 crore from Rs. 2,912 crore last year, with a revenue increase to Rs. 13,675 crore from Rs. 12,380 crore.

2. What were the key growth areas?
The India formulation segment grew by 13.8%, while Rest of World sales increased by 21%.

3. How much did Sunpharma invest in R&D during Q3?
The company invested Rs. 8,450 million, highlighting its commitment to innovation.

4. How did global specialty sales perform?
Global specialty sales reached $370 million, growing 17.5% excluding milestone payments.

5. What were the EBITDA margins for Q3?
The EBITDA margin stood at 29.3%, up from 28% last year.

Conclusion

Sunpharma’s Q3 results reflect steady growth and resilience despite challenges in the US market. With strong performance in the Indian and emerging markets and increased investments in specialty products, the company appears well-positioned for future growth. Continued focus on R&D and strategic shifts towards high-value segments will likely play a key role in sustaining this momentum.